Omnaris and Injection site swelling - a phase IV clinical study of FDA data

Summary:

Injection site swelling is reported as a side effect among people who take Omnaris (ciclesonide), especially for people who are female, 40-49 old, also take Xolair, and have Asthma.

The phase IV clinical study analyzes which people have Injection site swelling when taking Omnaris. It is created by eHealthMe based on reports of 3,841 people who have side effects when taking Omnaris from the FDA, and is updated regularly.

What is Omnaris?

Omnaris has active ingredients of ciclesonide. It is often used in allergies. eHealthMe is studying from 3,970 Omnaris users. Check the latest studies of Omnaris.

What is Injection site swelling?

Injection site swelling is found to be associated with 1,056 drugs and 1,116 conditions by eHealthMe. Check the latest studies of Injection site swelling.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

3,841 people reported to have side effects when taking Omnaris.
Among them, 20 people (0.52%) have Injection site swelling.

Could Omnaris cause Injection site swelling?

Among these 20 people:

What is the gender of people who have Injection site swelling when taking Omnaris? *

female: 85 %
male: 15 %

What is the age of people who have Injection site swelling when taking Omnaris? *

What are other drugs people take besides Omnaris? *

What are other side effects people have besides Injection site swelling? *

Injection Site Erythema (redness at injection site): 13 people, 65.00%
Injection Site Pain: 11 people, 55.00%
Head Injury: 11 people, 55.00%
Dyspnea (difficult or laboured breathing): 11 people, 55.00%
Dry Skin: 10 people, 50.00%
Weight Decreased: 10 people, 50.00%
Asthma: 10 people, 50.00%
Injection Site Pruritus (severe itching at injection site): 10 people, 50.00%
Wheezing (a high-pitched whistling sound made while you breath): 10 people, 50.00%
Middle Insomnia (difficulty returning to sleep after awakening either in the middle of the night): 10 people, 50.00%

What are the existing conditions these people have? *

Asthma: 12 people, 60.00%
Seasonal Allergy (allergic condition due to certain season): 6 people, 30.00%
Chest Pain: 5 people, 25.00%
Dyspnea (difficult or laboured breathing): 5 people, 25.00%
Hypersensitivity: 4 people, 20.00%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 10.00%
Middle Insomnia (difficulty returning to sleep after awakening either in the middle of the night): 2 people, 10.00%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 5.00%
Ankylosing Spondylitis (type of arthritis affecting the spine): 1 person, 5.00%
Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Omnaris and have Injection site swelling?

- Check whether Injection site swelling is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Omnaris:

Omnaris (3,970 reports)

Browse all side effects of Omnaris:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site swelling:

Injection site swelling (1,056 drugs)

Browse all the conditions that are associated with Injection site swelling:

Injection site swelling (1,116 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ciclesonide (the active ingredients of Omnaris) and Omnaris (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.